A Pitfall to Avoid When Using an Allergen Microarray: The Incidental Detection of IgE to Unexpected Allergens

Area of Science:

• Allergy diagnostics
• Immunology
• Molecular allergy testing

Background:

• Component-resolved diagnosis (CRD) offers advanced allergy detection.
• CRD identifies specific IgE antibodies to single allergen molecules, unlike traditional whole extracts.
• Advantages include precise allergen identification in polysensitized patients and distinguishing true sensitization from cross-reactivity.

Purpose of the Study:

• To highlight the benefits of component-resolved diagnosis in allergy management.
• To address the potential pitfalls of multiplex platforms in CRD, specifically unexpected findings like Hymenoptera venom sensitization.
• To discuss the clinical and legal dilemmas arising from these unexpected results.

Main Methods:

• Utilizing component-resolved diagnosis (CRD) via singleplex or multiplex platforms.
• Employing an immuno solid-phase allergen chip microarray capable of testing sensitivity to 112 allergens.
• Analyzing the implications of detecting IgE to unexpected allergens, such as insect venom.

Main Results:

• CRD enables identification of true allergens, differentiation from cross-reactive components, and improved immunotherapy selection.
• Multiplex platforms, like allergen chip microarrays, can detect IgE to unexpected allergens (e.g., Hymenoptera venom).
• Positive sensitization to insect venom in asymptomatic individuals is common with these platforms but often lacks clinical significance.

Conclusions:

• Component-resolved diagnosis significantly enhances allergy diagnostics and immunotherapy.
• Unexpected findings, such as Hymenoptera venom sensitization in non-reactive individuals, present diagnostic and management challenges.
• Current guidelines and clinical experience offer limited direction for managing these specific findings, necessitating further research and policy development.